

EXPRESS MAIL CERTIFICATE

Date 3/14/02 Label No. EV039139439US

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner for Patents, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

Name (Print) D. B. Peck

Signature D. B. Peck

Customer No.:



**07278**

PATENT TRADEMARK OFFICE

Docket No.: 3991/OK379

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Mark Andrew GUTHRIDGE; Michael Claude BERNDT; Frank Charles STOMSKI; Angel Francisco LOPEZ

Serial No.: t/b/a

Confirmation No.:

Filed: Concurrently Herewith

For: A BINDING MOTIF OF A RECEPTOR

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of  
Patents and Trademarks  
Washington, DC 20231

Sir:

In order to comply with 37 CFR 1.97 and 1.98, attached hereto is a copy of Form PTO-1449 and copies of the documents listed thereon.

J1003 U.S. PRO  
10/099895  
03/14/02

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing Form PTO-1449 next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

The undersigned is also enclosing herewith a copy of a Search Report issued November 28, 2000 for the PCT counterpart of the present patent application (Application No. PCT/AU00/0118), in which the presently disclosed references were cited. Since a translation of the Search Report is also enclosed, or the Search Report utilizes conventional codes to characterize each cited reference, it is believed that the applicants in the above-identified patent application have now met the "concise explanation" requirement of 37 C.F.R. 1.98.

This submission is filed within three months of the filing of the application.

The present Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56, but the citation of such document is not to be

construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

It is believed that no fee is due. However, if the Commissioner determines that a fee is due, the Commissioner is hereby authorized to charge the above deposit account for any deficiency.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,

Dated: March 14, 2002

  
\_\_\_\_\_  
Paul F. Fehlner, Ph.D.  
Registration No. 35,135  
Attorney for Applicant(s)

DARBY & DARBY  
805 Third Avenue  
New York, NY 10022  
(212) 527-7700

J1003 U.S. PTO  
10/09895  
03/14/02


**LIST OF REFERENCES CITED BY APPLICANT**

(Use Several Sheets if Necessary)

DOCKET NO.: 3991/OK379                    SERIAL NO: t/b/a  
 APPLICANT: Mark Andrew GUTHRIDGE        FILING DATE: Concurrently Herewith  
     CONFIRMATION NO:

**U.S. PATENT DOCUMENTS**

*EXAMINER <u>INITIALS</u>	<u>NUMBER</u>	DOCUMENT <u>DATE</u>	<u>NAME</u>	<u>CLASS</u>	<u>SUBCLASS</u>	<u>FILING DATE</u>
------------------------------	---------------	-------------------------	-------------	--------------	-----------------	--------------------

**FOREIGN PATENT DOCUMENTS**

*EXAMINER <u>INITIALS</u>	<u>NUMBER</u>	DOCUMENT <u>DATE</u>	<u>COUNTRY</u>	<u>CLASS</u>	<u>SUBCLASS</u>	TRANSLATION <u>YES</u> <u>NO</u>
------------------------------	---------------	-------------------------	----------------	--------------	-----------------	-------------------------------------

**OTHER REFERENCES**  
**(INCLUDING AUTHOR, TITLE DATE, PERTINENT PAGES, ETC.)**

\*EXAMINER  
INITIALS

1. The Journal of Biological Chemistry, Vol 269 No: 42 (1994) pages 26259-26266 (LEWIS, R. et al) "Phorbol Ester Stimulates Phosphorylation on Serine 1327 of the Human Insulin Receptor"
2. The Journal of Biological Chemistry Vol 268 No: 9 (1993) pages 6765-6770 (MERIDA, I et al) "The Serine-rich Cytoplasmic Domain of the Interleukin-2 Receptor β Chain is Essential for Interleukin-dependent Tyrosine Protein Kinase and Phosphatidylinositol-3 kinase Activation"
3. The Journal of Biological Chemistry, Vol 273 No: 16 (1998) pages 9365-9368 (CHARNG, MIN-JI et al) "A Novel Protein Distinguishes between Quiescent and Activated Forms of the Type I Transforming Growth Factor β Receptor"
4. The Journal of Biological Chemistry Vol 269 No: 3 (1994) pages 1815-1820 (GANDINO, L. et al) "Phosphorylation of Serine 985 Negatively Regulates the Hepatocyte Growth Factor Receptor Kinase"

LIST OF REFERENCES CITED BY APPLICANT

(Use Several Sheets if Necessary)

DOCKET NO.: 3991/OK379                    SERIAL NO: t/b/a  
APPLICANT: Mark Andrew GUTHRIDGE        FILING DATE: Concurrently Herewith  
    CONFIRMATION NO:

\*EXAMINER  
INITIALS

5. EMBO Journal Vol 8 No: 10 (1989) pages 2955-2965 (FREED, E et al) "A Novel Integrin  $\beta$  Integrin Subunit is Associated with the Vitronectin Receptor  $\alpha$  subunit ( $\alpha$ ) in a Human Osteosarcoma Cell Line and is a Substrate for Protein Kinase C"
6. Journal of Biotechnology Vol 37 (1994) pages 109-122 (BARDELLI, A et al) "Identification of Functional Domains in the Hepatocyte Growth Factor and its Receptor by Molecular Engineering"
7. The Biochemical Journal Vol 235 No: 1 (1986) pages 1-11 (GAMMELTOFT, S et al) "Protein Kinase Activity of the Insulin Receptor"
8. Stem Cells, Vol 16, No: 5 (1998) pages 301-313 (GUTHRIDGE, MA et al) "Mechanism of Activation of the GM-CSF, IL-3, and IL-5 family of Receptors"
9. The Journal of Biological Chemistry, Vol 274 No: 47 (1999) pages 33474-33479 (BONDAR, RJ et al) "The Cytoplasmic Domain of the Platelet Glycoprotein I $\alpha$  is Phosphorylated at serine 609"
10. Blood, Vol 95 No: 2 (2000) pages 551-557 (FENG S, et al) "Cytoplasmic Domains of Gplb $\alpha$  and Gplb $\beta$  regulate 14-3-3 $\zeta$  Binding to Gp1B/IX/V"
11. Blood, Vol 94 No: 6 (1999) pages 1933-1942 (STOMSKI, F C et al) "Identification of a 14-3-3 Binding Sequence in the Common  $\beta$  Chain of the Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Interleukin-3 (IL-3), and I-5 Receptors That is Serine-Phosphorylated by GM-CSF"

EXAMINER: \_\_\_\_\_

DATE CONSIDERED: \_\_\_\_\_

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.